loading page

  • +5
  • Julieta Castro,
  • Ana Niembro-Zúñiga,
  • Yadira Betanazos-Cabrera,
  • Gabriela Barrera-Villegas,
  • Daniel Ortiz-Morales,
  • Arroyo Acosta,
  • Marta Zapata Tarres
Julieta Castro
Hospital Central Sur de Alta Especialidad

Corresponding Author:[email protected]

Author Profile
Ana Niembro-Zúñiga
Instituto Nacional de Pediatria
Author Profile
Yadira Betanazos-Cabrera
Hospital de Especialidades Centro Medico Nacional Siglo XXI
Author Profile
Centro Medico Nacional 20 de Noviembre
Author Profile
Gabriela Barrera-Villegas
Centro Medico Nacional 20 de Noviembre
Author Profile
Daniel Ortiz-Morales
Hospital General de Mexico Dr Eduardo Liceaga
Author Profile
Arroyo Acosta
Hospital CIMA Hermosillo
Author Profile
Marta Zapata Tarres
Fundacion IMSS AC
Author Profile


Introduction: Brain tumors in children are the main cause of cancer related death in the pediatric population. Brainstem tumors incidence comprises 10.9% of all brain tumors having the Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) a fatal prognosis. Some countries have developed a national and international register database, to characterize their population. This study provides a retrospective population-based data to describe the epidemiology of children with DIPG in México from 2001-2021, and assesses the proposed prognostic factors previously described for survival outcome. Methods: Health Institutions from México were invited to fill in a retrospective registry of DIPG patients. Epidemiological, clinical, diagnostic, histopathologic and treatment variables were described. Fisher exact test was used to compare long, and short-term survivors and overall survival was estimated using the Kaplan-Meier Method. Differences between survival curves were evaluated using the Log-rank test and Cox proportional hazards regression analysis. Results: One-hundred and ten patients were included in the analysis. Median age at diagnosis was 7 years. Sixty patients (54.5%) presented with symptoms in less than 6 months being the most frequent ataxia (56.4%). Treatment was offered to 90 patients (81.8%), overall survival at 160 weeks (4 years) was 11.4%, and 16 patients (14.5%) arrived at clinical centers to die. We found no significant survival differences in any of the prognostic factors. Conclusion: This study highlights the need to develop improvement strategies to streamline healthcare processes and enhance quality of care to strengthen our situational diagnosis in Mexico.
10 Sep 2022Submission Checks Completed
10 Sep 2022Assigned to Editor
10 Sep 2022Submitted to Pediatric Blood & Cancer
18 Sep 2022Reviewer(s) Assigned
10 Oct 2022Review(s) Completed, Editorial Evaluation Pending
17 Oct 2022Editorial Decision: Revise Major
11 Nov 2022Submission Checks Completed
11 Nov 20221st Revision Received
11 Nov 2022Assigned to Editor
17 Nov 2022Review(s) Completed, Editorial Evaluation Pending
17 Nov 2022Reviewer(s) Assigned
27 Dec 2022Editorial Decision: Revise Major
24 Jan 20232nd Revision Received
24 Jan 2023Submission Checks Completed
24 Jan 2023Assigned to Editor
24 Jan 2023Review(s) Completed, Editorial Evaluation Pending
11 Feb 2023Reviewer(s) Assigned
27 Mar 2023Editorial Decision: Revise Major
31 Mar 20233rd Revision Received
31 Mar 2023Submission Checks Completed
31 Mar 2023Assigned to Editor
31 Mar 2023Review(s) Completed, Editorial Evaluation Pending
06 Apr 2023Reviewer(s) Assigned
28 Apr 2023Editorial Decision: Accept